# Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas

> **NCT03189186** · PHASE1 · WITHDRAWN · sponsor: **University of California, Irvine**

## Conditions studied

- Renal Cell Carcinoma
- Metastatic Kidney Cancer

## Interventions

- **DRUG:** Pembrolizumab Injection [Keytruda]
- **PROCEDURE:** Cryoablation
- **PROCEDURE:** Nephrectomy

## Key facts

- **NCT ID:** NCT03189186
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-01
- **Primary completion:** 2018-10-17
- **Final completion:** 2018-10-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was closed due to extremely low accrual, as well as a change in care when using the study drug.
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03189186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03189186, "Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03189186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*